Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer

Breast Cancer Research

Volumn 6, Issue 1, 2004, Pages 13-21

  Alkarain, Angel ^a   Slingerland, Joyce ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Breast cancer; Cell cycle; Cyclin dependent kinase; Deregulation; p27

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE; PROTEIN P27; PROTEIN TYROSINE KINASE; RAS PROTEIN; REGULATOR PROTEIN;

BREAST CANCER; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; ENZYME ACTIVATION; GENE MUTATION; GENETIC CODE; HUMAN; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RAS PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 1042280976     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr722     Document Type: Review

References (138)

1. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79: 551-555.
2. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995, 9:1149-1163.
3. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl 1994, 18:69-73.
4. Murray AW: Creative blocks: cell cycle checkpoints and feedback controls. Nature 1992, 359:599-604.
5. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992, 71: 543-546.
6. Morgan DO: Principles of CDK regulation. Nature 1995, 374: 131-134.
7. Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000, 183:10-17.
8. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13: 1501-1512.
9. LaBaer J, Garrett MID, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997, 11:847-862.
10. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999, 18:1571-1583.
11. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J: Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 1993, 260:536-539.
12. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994, 91:5291-5295.
13. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22.
14. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994, 14:3683-3694.
15. 1 arrest. Mol Cell Biol 2002, 22:2993-3002.
16. KiP1 accumulation during the cell cycle. Science 1996, 271:1861-1864.
17. Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997, 272:7093-7098.
18. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269: 682-685.
19. Kip1 in G1 and S phase. Nature 2001, 413:323-327.
20. Kip1. Gene 1996, 180:113-120.
21. KiP1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 1998, 17: 2619-2627.
22. KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998, 90:1284-1291.
23. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 1999, 18:3742-3753.
24. kip1. Nature 2000, 404:782-787.
25. Kip1 involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003, 14:201-213.
26. Kip1, a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 2000, 274:37-42.
27. Guan T, Kehlenbach RH, Schirmer EC, Kehlenbach A, Fan F, Clurman BE, Arnheim N, Gerace L: Nup50, a nucleoplasmically oriented nucleoporin with a role in nuclear protein export. Mol Cell Biol 2000, 20:5619-5630.
28. Muller D, Thieke K, Burgin A, Dickmanns A, Eilers M: Cyclin E mediated elimination of p27 requires its interaction with the nuclear pore associated protein mNPAP60. EMBO J 2000, 19: 2168-2180.
29. Kip1 and regulates cell cycle progression. EMBO J 2002, 21:3390-3401.
30. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S: p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001, 20:6672-6682.
31. Kip1. Genes Dev 1997, 11: 1464-1478.
32. Vlach J, Hennecke S, Amati 8: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997, 16:5334-5344.
33. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999, 13:1181-1189.
34. Ohta T, Michel JJ, Schottelius AJ, Xiong Y: ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999, 3:535-541.
35. Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1:193-199.
36. Skp2 complex through phosphorylated Thr187 in p27. Curr Biol 1999, 9:661-664.
37. Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999, 1:207-214.
38. Kip1. Mol Cell 2001, 7:639-650.
39. Skp2-mediated ubiquitinylation of p27. Nat Cell Biol 2001, 3:321-324.
40. Kip1 at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001, 276:48937-48943.
41. Kip1 is haplo-insufficient for tumour suppression. Nature 1998, 396:177-180.
42. Kip1 in human malignancies. Cancer Res 1995, 55:2266-2269.
43. Kip1 gene to 12p13 and its analysis in luekemias. Cancer Res 1995, 55:1206-1210.
44. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res 1995, 55:1211-1214.
45. kip1 deregulation in cancer: down-regulation or mislocalization? Cell Cycle 2002, 1:394-400.
46. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997, 94:6380-6385.
47. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997, 57:1259-1263.
48. Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997, 3: 2269-2274.
49. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett 1997, 234:127-130.
50. KIP1 in multistage colorectal carcinogenesis. Cancer Res 1998, 58:114-122.
51. Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998, 90:916-920.
52. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998, 58:1730-1735.
53. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998, 58:542-548.
54. Yang RM, Naitoh J, Murphy M, Wang HJ, Philipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945.
55. Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Cancer Res. 1999, 59:684-688.
56. Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D: Proteasome-dependent degradation of p27/kip1 in gliomas. J Neuropathol Exp Neurol 1999, 58:691-696.
57. KiP1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 1999, 5:551-557.
58. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234.
59. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997, 57:3381-3385.
60. Chiarle R, Budel L, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, DeWolf C, Inghirani G: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood (in press).
61. Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001, 91:1745-1751.
62. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T: High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001, 61:7044-7047.
63. Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M: Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001, 98:2515-2520.
64. Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J: A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002, 161:207-216.
65. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K, Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by SkP2 overexpression, possibly via p27 proteolysis. Cancer Res 2002, 62:3819-3825.
66. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001, 98:5043-5048.
67. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999, 94:765-772.
68. Kip1 is abrogated by c-Myc. EMBO J 1996, 15:6595-6604.
69. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999, 18:5321-5333.
70. Cip1. EMBO J 1999, 18:5310-5320.
71. Gartel AL, Shchors K: Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003, 283:17-21.
72. Weber JD, Hu W, Jefcoat SC Jr, Raben DM, Baldassare JJ: Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem 1997, 272:32966-32971.
73. Balmanno K, Cook SJ: Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999, 18: 3085-3097.
74. Sears RC, Nevins JR: Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002, 277:11617-11620.
75. Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2001, 14: 3102-3114.
76. Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
77. Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000, 10:3966-3972.
78. Blain SW, Massagué J: Breast cancer banishes p27 from nucleus. Nat Med 2002, 8:1076-1078.
79. Badassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S, Fusco A, Viglietto G: Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999, 104:865-874.
80. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999, 59:3790-3794.
81. kip1 correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol 2002, 33:1006-1015.
82. Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002, 8:1145-1152.
83. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002, 8:1136-1144.
84. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002, 8:1153-1160.
85. Moeller J, Head D, Sheaff RJ: p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol Cell Biol 2003, 23:3735-3752.
86. kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 2003, 23:216-228.
87. Aktas H, Cai H, Cooper GM: Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol 1997, 17:3850-3857.
88. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 1997, 15:629-637.
89. Takuwa N, Takuwa Y: Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1997, 17:5348-5358.
90. Kip1. J Biol Chem 2001, 276:2686-2692.
91. Alessandrini A, Chiaur DS, Erikson R, Pagano M: Regulation of the cyclin-depedent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997, 11:342-345.
92. Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA, Ladish HF, Henis YI: Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 2000, 19: 5926-5935.
93. Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997, 272:13-16.
94. Kip degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem 1999, 274:3396-3401.
95. Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res 2001, 61: 6583-6591.
96. Yang HY, Zhou BP, Hung MC, Lee MH: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem 2000, 275:24735-24739.
97. Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 2001, 276:40888-40895.
98. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998, 52:65-77.
99. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/Neu oncogene. Science 1987, 235:177-182.
100. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
101. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH: Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 2001, 30: 169-175.
102. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A: Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer 2003, 97:1591-1600.
103. Kip1-Cdk2 complex formation receptor overexpression does not determine growth dependency. Mol Cell Biol 2000, 20:3210-3223.
104. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994, 83:2038-2044.
105. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993, 75:175-185.
106. Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B: Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 1994, 179:1855-1865.
107. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 1996, 56:3589-3596.
108. Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997, 15:2333-2342.
109. 1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 2001, 10:599-604.
110. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK: Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 2002, 62: 6764-6769.
111. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62: 4132-4141.
112. Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 2000, 275:39223-39230.
113. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795-4805.
114. Kip1 induction in mouse Y1 adrenocortical tumor cells is dependent on both PKA activation and Akt/PKB inactivation. Biochemistry 2002, 41:10133-10140.
115. SKP2. Curr Biol 2001, 11:263-267.
116. Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, Krek W: The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J 2000, 19:5362-5375.
117. Yang G, Ayala G, Marzo AD, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002, 8: 3419-3426.
118. McManus EJ, Alessi DR: TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 2002, 4:E214-E216.
119. Marygold SJ, Leevers SJ: Growth signaling: TSC takes its place. Curr Biol 2002, 12:R785-R787.
120. Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998, 95:15653-15658.
121. kip cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994, 372:570-573.
122. Firpo EJ, Koff A, Solomon MJ, Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 1994, 14:4889-4901.
123. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997, 3:227-230.
124. kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997, 3:222-225.
125. Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G: Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 1999, 18:2557-2566.
126. De Paola F, Vecci AM, Granato AM, Liverani M, Monti F, Innoceta AM, Gianni L, Saragoni L, Ricci M, Falcini F, Amadori D, Volpi A: p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J Pathol 2002, 196:26-31.
127. Moriya T, Sakamoto K, Sasano H, Kawanaka M, Sonoo H, Manabe T, Ito J: Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod Pathol 2000, 13:13-18.
128. Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM: Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 1999, 435:116-124.
129. Soslow RA, Carlson DL, Horenstein MG, Osborne MP: A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat 2000, 61:161-170.
130. Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol 1999, 187:200-206.
131. kip1 in node-positive breast cancer. J Surg Oncol 1999, 70:230-234.
132. Kip1 and apoptosis in human breast cancer. Br J Cancer 1999, 79:1572-1578.
133. kip1 expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 2000, 89:236-241.
134. Leong ACK, Hanby AM, Potts HWW, Tan DSP, Skilton D, Ryder K, Harris WH, Liebmann RD, Barnes DM, Gillett CE: Cell cycle proteins do not predict the outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer 2000, 89:26-31.
135. Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol 2000, 18:4045-4052.
136. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C: p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001, 67:15-22.
137. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996, 74: 208-215.
138. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66.